vTv Therapeutics Inc
Change company Symbol lookup
Select an option...
VTVT vTv Therapeutics Inc
BUGDF Bumrungrad Hospital PCL
ORCL Oracle Corp
OPTT Ocean Power Technologies Inc
SPEYF Spey Resources Corp
BCTX Briacell Therapeutics Corp
JAZZ Jazz Pharmaceuticals PLC
KRT Karat Packaging Inc
REMRF Red Moon Resources Inc
ARR ARMOUR Residential REIT Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Price
Delayed
$2.53
Day's Change
0.1693 (7.17%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.83
Day's Low
2.48
Volume
(Heavy Day)

Today's volume of 18,124,724 shares is on pace to be much greater than VTVT's 10-day average volume of 1,787,956 shares.

18,124,724

Company Profile

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
27.49x
Price/Book (MRQ)
--
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

May 2021
Current Month
2.3M
Previous Month
2.6M
Percent of Float
14.83%
Days to Cover
1.5702 Days

Share Information

VTVT is in a share class of common stock
Float
2.6M
Shares Outstanding
83.3M
Institutions Holding Shares
57
7.67%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Robin E. AbramsChmn.
  • Stephen L. HolcombePres.
  • Rudy C. HowardCFO
  • Hersh KozlovDir.
  • Richard NelsonDir.

Address

Insider Trading

During the most recent quarter, 70K shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.